<DOC>
	<DOC>NCT01008943</DOC>
	<brief_summary>The Autologous Cell Therapy for Female SUI study is a clinical trial to determine the safety and potential effectiveness of a single dose of 200 million Cook MyoSite Autologous Muscle Derived Cells for treatment of Stress Urinary Incontinence.</brief_summary>
	<brief_title>Autologous Cell Therapy for Female Stress Urinary Incontinence</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence, Stress</mesh_term>
	<criteria>SUI with normal detrusor activity confirmed with urodynamics Bladder capacity &gt;200 ml Incontinence has not shown any improvement for at least 6 months Failed prior treatments (e.g., behavior modification, bladder exercises, biofeedback, electrical stimulation, bulking injections, urethral suspensions and/or drug therapy) Known vesicoureteral reflux, vaginal prolapse beyond the introitus, or other significant pelvic floor abnormalities with high pressure instability Neuromuscular disorder (e.g., muscular dystrophy, multiple sclerosis) Uncontrolled diabetes Pregnant, lactating, or plans to become pregnant during course of the study Morbid obesity (defined as 100 pounds over their ideal body weight, or BMI â‰¥40) and not expected to benefit from treatment Current or acute conditions involving cystitis or urethritis Scheduled to receive radiation treatment to the vicinity, or history of radiation treatment to the urethra or adjacent structures</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>